Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 3, 2003, Pages 236-240

  Schaefer, Paul L ^a   Marks, Randolph S ^b   Mahoney, Michelle R ^b   Sloan, Jeff A ^b   Bauman, Mitchell D ^c   Tazelaar, Henry D ^b   Kugler, John W ^d   Mailliard, James A ^e   Ebbert, Larry P ^f   Wiesenfeld, Martin ^g  

^a Toledo Community Hospital Oncology Program CCOP   (United States)

^b MAYO CLINIC   (United States)

^c Siouxland Hematology Oncology Associates   (United States)

^d Illinois Oncol Res Assoc CCOP   (United States)

^e MISSOURI VALLEY CANCER CONSORTIUM   (United States)

^f Rapid City Regional Oncology Group   (United States)

^g Cedar Rapids Oncology Project CCOP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; TOPOTECAN;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REGIMEN; FEMALE; HUMAN; INFECTION; LETHARGY; LEUKOPENIA; LIVER TOXICITY; LUNG SMALL CELL CANCER; LUNG TOXICITY; MALE; MORTALITY; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TOPOTECAN; TREATMENT OUTCOME;

EID: 0038178976     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200306000-00005     Document Type: Article

References (15)

1. Jemal A, Murray T, Samuels A, et al. Cancer Statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Bonner JA, Sloan JA, Shanahan TG, et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 1999;17:2681-91.
3. Maksymiuk AW, Jett JR, Earle JD, et al. Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: Results of a North Central Cancer Treatment Group randomized clinical trial. J Clin Oncol 1994;12:70-6.
4. Marks RS, Sloan JA, Hillman SL, et al. Empirically based evidence for determination of stratification factors and interpretation of toxicity profiles: a patient-level meta-analysis of North Central Cancer Treatment Group (NCCTG) and Mayo Clinic lung cancer clinical trials. Proc Am Soc Clin Oncol 1999;18:1865.
5. Hsiang YH, Liu SH. Identification of mammalian topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;48:1722-6.
6. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989;59:351-75.
7. Johnson RK, Hertzberg RP, Kingsbury WD, et al. Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I in antitumor activity. J Med Chem 1991;34:98-107.
8. Rowinsky EK, Grochow LB, Hendricks CB, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992;10:647-56.
9. Burris HA III, Awada A, Kuhn JG, et al. Phase I in pharmacokinetic studies of topotecan administered as a 72- or 120-hour continuous infusion. Anticancer Drugs 1994;5:394-402.
10. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993;85:271-91.
11. Duffy DE, Santner TJ. Confidence intervals for a binomial parameter based on multistage tests. Biometrics 1987;43:81-93.
12. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
13. Weitz JJ, Marschke RF Jr, Sloan JA, et al. A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. Lung Cancer 2000;28:157-62.
14. Schiller JH, Kim K, Hudson P, et al. Phase II study of topotecan in patients with extensive stage small cell carcinoma of the lung: Eastern Cooperative Oncology Group trial. J Clin Oncol 1996;14: 2345-52.
15. vonPawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small cell lung cancer. J Clin Oncol 1999;17:658-67.